Skip to main content

Table 2 Main categories with sub-categories, with example quotes from the interview

From: Priority setting at the clinical level: the case of nusinersen and the Norwegian national expert group

Category

Example quote

Rationing treatment?

“The challenge is, in a way, to be able to pick out those who have insufficient effect. And what is sufficient effect? There are these borderlands that are very difficult”

The weakness of “objective” criteria

“These measurements are not perfect, and they are a pseudo-measure, we think, for quality of life, really. Which is very hard to measure”

Members’ overall assessment of the group

“The expert group I think has worked very well, I think it’s a very good model for other similar rare diseases”

New ethical dilemmas

 

 Quality of life

“But the [SMA] 1’s are the dilemma that we, that I, prevent from dying, and that we often ‘convert’ to poor [SMA] 2’s”

 Disagreement

 

 Resource use

“In any case there are delays, and that [SMA patients] take up a very large part of our department, that’s clearly the feedback from our colleagues, they think it’s far too many Spinrazas [i.e., nusinersen treatments]”